Geron Corporation: A lot is riding on Imetelstat!
Geron Corporation, Inc. (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor, imetelstat, intended to treat hematologic malignancies. The Company’s lead candidate Imetelstat is a novel first-in-class telomerase inhibitor currently undergoing a Phase 3 trial, IMerge, which is a double-blind, randomized,...
